Alkermes plc Stock price

Equities

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
27.25 USD +1.76% Intraday chart for Alkermes plc -1.66% -1.77%
Sales 2024 * 1.53B Sales 2025 * 1.54B Capitalization 4.55B
Net income 2024 * 356M Net income 2025 * 332M EV / Sales 2024 * 2.42 x
Net cash position 2024 * 851M Net cash position 2025 * 1.26B EV / Sales 2025 * 2.14 x
P/E ratio 2024 *
13.1 x
P/E ratio 2025 *
14.8 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.76%
1 week-1.66%
Current month-8.22%
1 month-8.25%
3 months-2.89%
6 months-4.59%
Current year-1.77%
More quotes
1 week
26.75
Extreme 26.75
27.57
1 month
26.75
Extreme 26.75
30.41
Current year
26.18
Extreme 26.18
32.88
1 year
22.01
Extreme 22.01
33.71
3 years
18.43
Extreme 18.43
33.71
5 years
11.98
Extreme 11.98
37.75
10 years
11.98
Extreme 11.98
80.71
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 91-01-31
Director of Finance/CFO 51 98-12-31
President 61 11-08-31
Members of the board TitleAgeSince
Chief Executive Officer 62 91-01-31
Director/Board Member 72 16-05-25
Director/Board Member 62 20-12-09
More insiders
Date Price Change Volume
24-03-27 27.25 +1.76% 1,464,402
24-03-26 26.78 -1.94% 1,345,218
24-03-25 27.31 +0.07% 907,592
24-03-22 27.29 +1.19% 1,898,087
24-03-21 26.97 -2.67% 2,037,853

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
27.25 USD
Average target price
34.83 USD
Spread / Average Target
+27.83%
Consensus
  1. Stock
  2. Equities
  3. Stock Alkermes plc - Nasdaq